BioWorld

Dec. 16, 2004

Eyeing Cancer Drugs, Aphton Acquiring Igeneon For $81M

Aphton Corp. entered a definitive agreement to acquire the privately held Vienna, Austria-based company Igeneon AG for more than $81 million in equity. (BioWorld Today) Read More

Genta Stock Sale Gets $22.5M; Genasense NDA Coming Soon

Antimicrobial Dermatology Deal Could Be Worth $14M To Ansata

With New Approach To LSDs, ZyStor Gets $8.5M First Round

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...